Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
1.280
+0.010 (0.79%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Cabaletta Bio Stock Forecast
CABA's stock price has decreased by -90.12% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Cabaletta Bio stock have an average target of 21, with a low estimate of 3.00 and a high estimate of 50. The average target predicts an increase of 1,540.62% from the current stock price of 1.28.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cabaletta Bio stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Buy | 5 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $6 → $3 | Hold | Maintains | $6 → $3 | +134.38% | Apr 1, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +1,696.88% | Apr 1, 2025 |
| UBS | UBS | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +446.88% | Apr 1, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $30 → $22 | Buy | Maintains | $30 → $22 | +1,618.75% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +1,853.13% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
n/a
from 367.02M
Revenue Next Year
n/a
EPS This Year
-2.31
from -2.36
EPS Next Year
-2.16
from -2.31
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 36.8M | 21.0M | 26.3M | ||
| Avg | 7.1M | 4.1M | 5.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -90.0% | 194.1% | 543.4% | ||
| Avg | -98.1% | -42.9% | 25.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.28 | -0.89 | -0.92 | ||
| Avg | -2.31 | -2.16 | -1.99 | ||
| Low | -2.86 | -3.08 | -2.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.